BioDelivery Sciences (BDSI) Reports Q2 EPS of $0.01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioDelivery Sciences Reports Strong Q2 2020 Results
August 5, 2020 7:45 AM EDTSecond Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million
Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million
BELBUCA and Symproic® Each Reach All Time High TRx Volume and Market Share
Conference Call and Webcast Scheduled for 8:30 AM EST Today
RALEIGH, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported... More
